Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Profound Medical (PROF) EBITDA Margin (2019 - 2026)

Profound Medical has reported EBITDA Margin over the past 7 years, most recently at 132.17% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 3342.0% year-over-year to 132.17%; the TTM value through Dec 2025 reached 250.27%, up 4462.0%, while the annual FY2025 figure was 250.26%, 3662.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 132.17% at Profound Medical, up from 166.1% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 1620.76% in Q4 2022 and troughed at 6838.5% in Q4 2023.
  • A 5-year average of 451.57% and a median of 55.42% in 2021 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 671635bps in 2022 and later crashed -845927bps in 2023.
  • Year by year, EBITDA Margin stood at 5095.59% in 2021, then surged by 132bps to 1620.76% in 2022, then tumbled by -522bps to 6838.5% in 2023, then surged by 98bps to 165.59% in 2024, then grew by 20bps to 132.17% in 2025.
  • Business Quant data shows EBITDA Margin for PROF at 132.17% in Q4 2025, 166.1% in Q3 2025, and 587.16% in Q2 2025.